Biora Therapeutics Inc Quick Ratio (BIOR) starting from the second quarter 2026 to second quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Biora Therapeutics Inc   (NASDAQ: BIOR)

Biora Therapeutics Inc 's Quick Ratio

BIOR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Biora Therapeutics Inc 's Cash & cash equivalent grew by % in the Q2 2026 sequentially, while Current Liabilities decreased, this led to improvement in Biora Therapeutics Inc 's Quick Ratio to 0.57, Quick Ratio remained below Biora Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 477 other companies have achieved higher Quick Ratio than Biora Therapeutics Inc in second quarter 2026. While total ranking remained the same in the Q2 2026 compared to the third quarter 2024 at no. .

Explain Quick Ratio?
How much Cash & cash equivalents BIOR´s has?
What are BIOR´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BIOR Quick Ratio (Jun 30 2026)
Q2		 (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2		 (Mar 31 2024)
Q1		 (Dec 31 2023)
Q4
Y / Y Current Liabilities Change 62.03 % 166.68 % 189.68 % 738.32 % 2.45 %
Y / Y Cash & cash equivalent Change - - - - -
Quick Ratio MRQ 0.57 - - - -
BIOR's Total Ranking # # # # 1055 # 2527
Seq. Current Liabilities Change -67.93 % 162.25 % -10 % 114.04 % -47.21 %
Seq. Cash & cash equivalent Change - - - - -



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 478
Healthcare Sector # 886
Overall Market # 3167


Quick Ratio Statistics
High Average Low
5 1.54 0.01
(Mar 31 2023)   (Dec 31 2010)




Financial Statements
Biora Therapeutics Inc 's Current Liabilities $ 39 Millions Visit BIOR's Balance sheet
Biora Therapeutics Inc 's Cash & cash equivalent $ 22 Millions Visit BIOR's Balance sheet
Source of BIOR's Sales Visit BIOR's Sales by Geography


Cumulative Biora Therapeutics Inc 's Quick Ratio

BIOR's Quick Ratio for the trailling 12 Months

BIOR Quick Ratio

 (Jun 30 2026)
12 Months		 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months		 (Mar 31 2024)
12 Months		 (Dec 31 2023)
12 Months
Y / Y Current Liabilities TTM Growth 181.52 % 166.93 % 128.71 % 39.75 % -34 %
Y / Y Cash & cash equivalent TTM Growth -28.09 % - - - -83.38 %
Quick Ratio TTM 0.09 - - - 0.33
Total Ranking TTM # # 2527
Seq. Current Liabilities TTM Growth 6.13 % 45.36 % 22.13 % 49.42 % 0.63 %
Seq. Cash & cash equivalent TTM Growth - - - - -50.02 %

Quick ratio ranking by company, industry and sector >> Back to BIOR Financial Strength Comparisons >> Go to Compare BIOR Quick Ratio to its Competitors

On the trailing twelve months basis BIOR Cash & cash equivalent remained unchanged by % in Q2 2026 year on year, faster than Current Liabilities, this led to